Arimidex lowers oestrogen production by blocking aromatase, an enzyme involved in making oestrogen after menopause. It is used as hormone therapy for eligible people with hormone receptor-positive breast cancer. Lower oestrogen exposure can reduce stimulation of cancer cells that depend on this hormone.
Arimidex is the oral tablet form of anastrozole, a non-steroidal aromatase inhibitor. Aromatase inhibitors are medicines used in hormone therapy when breast cancer cells carry receptors that respond to oestrogen. The aim is to reduce hormonal stimulation of the tumour and lower the risk of recurrence or control disease that has spread.
Anastrozole may be used for primary breast cancer after surgery, as extended endocrine treatment after an earlier hormone-treatment course, or for advanced and metastatic disease when the oncology team considers hormone treatment appropriate.
The treatment goal differs by setting. In early disease, the intention may include reducing the risk of recurrence. In metastatic disease, treatment may aim to slow progression, reduce symptoms or maintain disease control for as long as the cancer remains responsive.
| Treatment setting | Main clinical purpose |
|---|---|
| Early or primary breast cancer | Reduce the chance of hormone-sensitive recurrence after local treatment |
| Extended endocrine treatment | Continue hormonal protection after an earlier course when the balance remains favourable |
| Advanced or metastatic disease | Slow hormone-sensitive cancer growth and support disease control |
Arimidex may form part of adjuvant treatment after surgery for hormone receptor-positive breast cancer. Adjuvant means treatment given after the main local treatment to reduce the chance of cancer returning elsewhere in the body.
The benefit is a reduction in risk, not a guarantee that recurrence cannot occur. Duration is set by the oncology team and may change if side effects, bone health or other clinical factors alter the balance of treatment.
Metastatic breast cancer has spread beyond the original breast or nearby lymph nodes. Anastrozole may be used when the cancer remains hormone-sensitive and the expected benefit justifies treatment.
Treatment may be combined or sequenced with other anticancer medicines. The choice depends on previous endocrine therapy, tumour behaviour, menopausal status, symptoms and results from follow-up assessments.
Arimidex works by reducing the body’s production of oestrogen rather than by removing every molecule of oestrogen. Anastrozole binds to aromatase and limits the conversion of androgen precursors into oestrogen. This lowers exposure of oestrogen receptor-positive breast cancer cells to one of the signals that may support their growth.
After menopause, the ovaries produce far less oestrogen, but smaller amounts continue to arise through aromatase activity in peripheral tissues. Anastrozole targets this remaining production pathway.
The effect is biochemical, not immediate symptom relief. A person may not feel a measurable change in hormone levels, and symptoms alone cannot show whether treatment is controlling the cancer.
ER-positive breast cancer cells contain oestrogen receptors. When oestrogen activates these receptors, cellular growth signals may increase. Reducing oestrogen can reduce that stimulation, which is why endocrine treatment forms part of care for selected breast neoplasms.
NICE guidance and European oncology practice place hormone treatment within a wider plan that may include surgery, radiotherapy, chemotherapy or targeted treatment, depending on the tumour profile [1].
Arimidex is not suitable for everyone. The following situations require a clear treatment decision from the oncology team:
Tamoxifen and oestrogen-containing medicines can interfere with the clinical rationale for aromatase inhibition. Tell the oncology team about prescription medicines, hormonal products, supplements and treatments for osteoporosis before therapy begins.
NOT for you if: you are pregnant, breastfeeding, allergic to anastrozole, or considering treatment without appropriate ovarian suppression; discuss alternatives with the oncology team.
Lower oestrogen can affect several tissues. Common treatment effects include joint or muscle pain, stiffness, hot flushes, sweating, tiredness, low mood, sleep disturbance and vaginal dryness. The UK Summary of Product Characteristics describes the recognised adverse-effect profile and its frequency categories [2].
Joint pain is one of the most practical barriers to continued treatment. Morning stiffness may be worse after sitting still and can affect hands, knees, hips or shoulders. Persistent or disabling symptoms deserve clinical review because symptom management, supervised exercise or a change in endocrine treatment may be considered.
Other possible effects include:
Do not assume every new symptom comes from Arimidex. New chest symptoms, severe breathlessness, neurological changes or rapidly worsening pain require assessment rather than self-treatment.
Oestrogen helps maintain bone strength. Long-term aromatase inhibitor treatment can accelerate bone loss and increase fracture risk in susceptible patients. A baseline fracture-risk assessment or bone-density scan may be considered, with follow-up based on individual risk.
Calcium intake, vitamin D status, resistance exercise and weight-bearing activity may support bone health. Bone-protective treatment is prescribed for selected patients after clinical assessment; supplements are not automatically appropriate for everyone.
Blood clots are not the defining adverse effect of aromatase inhibitors, though clot symptoms still require urgent attention because DVT can lead to pulmonary embolism. Seek emergency medical help for sudden breathlessness, sharp chest pain, coughing blood, fainting or a racing heartbeat.
Possible DVT signs include new one-sided calf or thigh swelling, warmth, redness or pain. Do not massage a swollen leg while waiting for urgent assessment.
New vaginal bleeding after menopause needs medical assessment. It should not be dismissed as an expected side effect.
Anastrozole is the active ingredient associated with Arimidex in UK and international oncology references. The prescribed amount is individualised for each person rather than being one fixed amount for every patient. The treatment plan depends on pathology results, menopausal status, previous cancer treatment and the clinical stage of disease.
Aromatase is an enzyme that helps convert androgen hormones into oestrogen in tissues such as fat, muscle and the adrenal system. Anastrozole inhibits this enzyme. It belongs to the aromatase inhibitor group rather than the selective oestrogen receptor modulator group.
A useful practical distinction is that Arimidex reduces oestrogen production, while some other hormone treatments mainly alter how oestrogen receptors respond to the hormone.
Arimidex may be prescribed when laboratory testing shows hormone receptor-positive breast cancer. This means the cancer cells have receptors that can receive signals from oestrogen or related hormones. Receptor testing is performed on tumour tissue and is separate from a person’s symptoms.
The medicine is used in selected postmenopausal patients and in some premenopausal patients receiving ovarian suppression. It does not suit every breast cancer subtype.
Arimidex is taken by mouth as a tablet, using the schedule prescribed by the oncology team. The prescribed amount is individualised, and treatment is generally planned as a regular daily routine when the oncology prescription specifies daily use.
Arimidex can generally be taken with or without food according to UK product information. A fixed morning or evening time is not required for every patient; consistency is more useful than choosing a particular hour.
Arimidex and tamoxifen are both used in hormone therapy, but they work through different pathways. Arimidex lowers oestrogen production, while tamoxifen blocks oestrogen receptor signalling in breast tissue.
| Treatment | Main mechanism and practical trade-off |
|---|---|
| Arimidex | Aromatase inhibition; joint symptoms and bone loss require attention |
| Tamoxifen | Oestrogen-receptor modulation; clot and endometrial risks require attention |
Postmenopausal patients may be offered an aromatase inhibitor because ovarian oestrogen production has naturally declined. Tamoxifen remains relevant in different clinical situations, including some premenopausal treatment plans.
Premenopausal use of Arimidex generally requires ovarian suppression. Tumour biology, age, menopausal status, recurrence risk, previous treatment and tolerability all influence the choice.
Aromatase inhibitors may provide strong protection against hormone-sensitive recurrence for selected postmenopausal patients, yet joint and bone problems can make continued treatment difficult. Tamoxifen may be easier for some people from a bone-health perspective, but it carries recognised risks involving venous thrombosis and the uterine lining.
NICE endocrine-treatment guidance supports individualised selection rather than treating one option as universally superior [3].
The mistakes below can reduce treatment continuity or delay recognition of complications:
In clinical practice, oncology teams usually focus on three questions: is the tumour hormone-sensitive, is the patient receiving enough endocrine coverage, and are side effects manageable enough to maintain treatment? A patient who stops tablets silently may lose part of the intended protection, while a patient who reports symptoms early may have several management options.
Monitoring can include symptom review, adherence discussion, bone-health assessment, cholesterol testing or other investigations selected for the person’s risk profile. Symptoms do not provide a complete measure of treatment benefit. Imaging and examination may be used when clinically indicated. The oncology team interprets these findings alongside treatment tolerance. Routine blood tests do not measure every aspect of response.
Follow-up plans vary according to early or metastatic disease, recurrence risk, bone density, menopausal status and other treatment. Ask whether ovarian suppression remains active when Arimidex is used before natural menopause.
New bone pain, a suspected fracture, severe weakness, chest pain or breathlessness should be assessed promptly. The MHRA safety information for medicines supports reporting suspected serious adverse reactions through established UK monitoring routes [4].
Arimidex contains anastrozole, an aromatase inhibitor used in selected hormone receptor-positive breast cancer treatment plans. It reduces oestrogen production and may be used after surgery or for advanced disease, depending on tumour biology and menopausal status. The EMA product information reviewed in 2024 describes anastrozole’s endocrine mechanism and clinical indications [5].
The best time is the time that fits the prescribed schedule and can be maintained consistently. Arimidex may generally be taken with or without food, so breakfast is not medically required unless it helps establish a routine. UK product information available through the MHRA in 2025 supports regular oral administration without requiring one universal clock time.
Stopping Arimidex does not usually require a gradual dose reduction because it is not a corticosteroid or opioid medicine. The important issue is that stopping can remove the intended endocrine treatment, so recurrence-risk protection or disease control may be affected. NICE guidance reviewed in 2024 supports discussing planned treatment duration and side effects with the oncology team before stopping.
Regular weight-bearing and resistance activity may support muscle and bone health, while a balanced diet helps maintain general treatment resilience. No particular food can replace endocrine therapy or reliably increase anastrozole’s anticancer action. The WHO cancer-control guidance published in 2023 supports physical activity, tobacco avoidance and moderation of alcohol as part of supportive cancer care.
Arimidex is designed for regular dosing rather than symptom-based use. A single tablet contributes to ongoing aromatase inhibition, while the treatment plan maintains the effect through repeated doses. Pharmacology references reviewed by the British National Formulary in 2025 describe anastrozole as a medicine used on a regular schedule, not as an occasional tablet.
A reduction in oestrogen production begins through enzyme inhibition, but cancer-treatment benefit is assessed over follow-up rather than by an immediate sensation. Side effects may appear before any clinical response can be measured, and the absence of symptoms does not mean treatment is failing. NICE guidance reviewed in 2024 supports clinical review, imaging and disease-specific assessments rather than relying on how a person feels alone.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Kate, 69 - Middlesbrough, took her prescribed tablet daily for several months: “The hot flushes were manageable, but the stiffness in my fingers made mornings slow. I started recording it and the oncology nurse helped me discuss options instead of simply stopping.”
Sarah, 33 - Wolverhampton, used Arimidex with ovarian suppression: “The first weeks were confusing because tiredness and sleep problems appeared together. The treatment plan made more sense after my team explained why ovarian suppression was needed, although keeping up with both parts felt demanding.”
Charlotte, 35 - London, continued treatment after surgery: “I found walking and gentle strength work helped me feel less stiff. I still had difficult days and did not notice an immediate change, but the regular follow-up gave me a clearer way to judge whether the plan was tolerable.”
